𝔖 Bobbio Scriptorium
✦   LIBER   ✦

Reducing the risk of recurrence in postmenopausal women with early breast cancer: a role for aromatase inhibitors

✍ Scribed by Nicholas J. Robert

Book ID
118628414
Publisher
Frontline Medical Communications, Inc.
Year
2006
Tongue
English
Weight
154 KB
Volume
3
Category
Article
ISSN
1548-5315

No coin nor oath required. For personal study only.

πŸ“œ SIMILAR VOLUMES

Summary of aromatase inhibitor clinical
Summary of aromatase inhibitor clinical trials in postmenopausal women with early breast cancer
✍ Aman U. Buzdar; R. Charles Coombes; Paul E. Goss; Eric P. Winer πŸ“‚ Article πŸ“… 2008 πŸ› John Wiley and Sons 🌐 English βš– 115 KB

Five years of adjuvant therapy with tamoxifen was considered the gold-standard treatment for postmenopausal women with estrogen receptor-positive breast cancer for many years. Data from a core group of clinical trials investigating the safety and efficacy of aromatase inhibitors (AIs) have challenge

Do adjuvant aromatase inhibitors increas
Do adjuvant aromatase inhibitors increase the cardiovascular risk in postmenopausal women with early breast cancer : Meta-analysis of randomized trials
✍ Federica Cuppone; Emilio Bria; Sunil Verma; Kathleen I. Pritchard; Sonal Gandhi; πŸ“‚ Article πŸ“… 2008 πŸ› John Wiley and Sons 🌐 English βš– 203 KB πŸ‘ 1 views

## Abstract ## BACKGROUND. Despite the advantages from using aromatase inhibitors (AIs) compared with tamoxifen for early breast cancer, an unexpectedly greater number of grade 3 and 4 cardiovascular events (CVAE) (as defined by National Cancer Institute of Canada‐Common Toxicity Criteria [version